Vanda Pharmaceuticals (NASDAQ:VNDA) Announces Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Key Points

• Vanda Pharmaceuticals reported a quarterly loss of ($0.46) EPS, missing expectations by ($0.12) and also experiencing lower revenue of $52.59 million compared to the anticipated $54.77 million.
• The company updated its FY 2025 guidance, indicating potential shifts in financial outlook for investors.
• Recently, Vanda's stock price decreased to $4.19, down from a 52-week high of $5.56, reflecting investor sentiment following the earnings report.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.12), Zacks reports. The firm had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals updated its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA traded up $0.01 during trading on Wednesday, hitting $4.22. The company's stock had a trading volume of 485,029 shares, compared to its average volume of 575,770. The company has a market cap of $249.36 million, a PE ratio of -3.73 and a beta of 0.72. The business's 50 day simple moving average is $4.63 and its 200-day simple moving average is $4.54. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $5.55.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The stock was purchased at an average price of $4.40 per share, with a total value of $44,000.00. Following the completion of the acquisition, the chief executive officer directly owned 2,325,731 shares of the company's stock, valued at $10,233,216.40. This trade represents a 0.43% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 7,000 shares of Vanda Pharmaceuticals stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $4.59, for a total value of $32,130.00. Following the sale, the director directly owned 97,082 shares of the company's stock, valued at $445,606.38. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders own 8.90% of the company's stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

An institutional investor recently raised its position in Vanda Pharmaceuticals stock. Millennium Management LLC boosted its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 220.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,139,591 shares of the biopharmaceutical company's stock after acquiring an additional 1,470,898 shares during the quarter. Millennium Management LLC owned 3.63% of Vanda Pharmaceuticals worth $9,821,000 at the end of the most recent reporting period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VNDA has been the topic of several research analyst reports. Wall Street Zen downgraded Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.